Drug intelligence / Profile preview

NCR100

Development stage: Phase 2
Lead developer: Nuwacell Biotechnologies
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

NCR100 is a cell therapy product consisting of human induced pluripotent stem cell-derived mesenchymal-like cells, developed for the treatment of knee osteoarthritis. The therapy involves injecting these stem cell-derived mesenchymal stromal cells into the affected joint, with the aim to reduce inflammation and promote tissue repair in osteoarthritic knees. The drug is being developed by Nuwacell Biotechnologies and has reached Phase 2 clinical trials for knee osteoarthritis. Its mechanism of action is based on the regenerative and immunomodulatory properties of mesenchymal-like cells derived from induced pluripotent stem cells[1][2][3].

Brand names: NCR100NCR-100NCR 100
Other names: NCR-100NCR100NCR 100

Beyond the preview

Go deeper on NCR100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCR100.

Explore the full profile